Istesso, the company developing the first oral regenerative medicines, today announces the appointment of Dr Andrea Haynes as Head of Translational Science, effective immediately.

Dr Haynes brings more than 30 years’ experience in the pharmaceutical and biotechnology industries, with deep expertise in translating innovative science into clinical development programmes. She spent 31 years at GSK, where she held roles of increasing seniority and was accountable for delivering translational strategies and high-quality data packages to advance a diverse portfolio from discovery through early clinical development.

Her work has spanned multiple therapeutic areas and includes Phase 1 and Phase 2 programmes addressing diseases of significant unmet medical need, including rare cancers, autoimmune conditions and metabolic disorders. Throughout her career, she has built cross-functional teams focused on rigorous science, clear clinical hypotheses and data-driven decision-making.

“I’m excited to join the Istesso team and look forward to leveraging my experience to accelerate the development of these novel repair-enhancing molecules,” said Dr Haynes. “The opportunity to help bring forward a new class of regenerative medicines with the potential to transform patient outcomes is incredibly compelling.”

“We are delighted to welcome Andrea to Istesso,” said Dr Lisa Patel, Chief Executive Officer. “Her experience in designing and executing robust translational strategies, and in progressing assets into later-stage development, will be invaluable as we advance our unique repair-enhancing pipeline through clinical trials.”